Vedolizumab is associated with changes in innate rather than adaptive immunity in patients with inflammatory bowel disease.

Zeissig S, Rosati E, Dowds CM, Aden K, Bethge J, Schulte B, Pan WH, Mishra N, Zuhayra M, Marx M, Paulsen M, Strigli A, Conrad C, Schuldt D, Sinha A, Ebsen H, Kornell SC, Nikolaus S, Arlt A, Kabelitz D, Ellrichmann M, Lützen U, Rosenstiel PC, Franke A, Schreiber S (2018); Gut. pii: gutjnl-2018-316023. doi: 10.1136/gutjnl-2018-316023